Aadi Bioscience, Inc.
Clinical trials sponsored by Aadi Bioscience, Inc., explained in plain language.
Commercial-stage biopharmaceutical company focused on mTOR inhibitors for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo therapy targets hard-to-treat endometrial cancer Results expected Dec 2026 (estimated)
-
New hope for cancer patients with liver issues: experimental drug enters early testing
Disease control Recruiting nowThis early-stage study tests an experimental drug called nab-sirolimus in adults with advanced solid tumors who also have moderate liver impairment. The goal is to find a safe dose and see how the drug behaves in the body. About 28 participants will take part to help guide future…
Phase 1 • Sponsor: Aadi Bioscience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New combo therapy targets hard-to-treat endometrial cancer
Disease control Recruiting nowThis study tests a combination of two drugs, nab-sirolimus and letrozole, in 29 people with advanced or recurrent endometrioid endometrial cancer that cannot be removed by surgery. The goal is to see if the combination shrinks tumors or slows cancer growth. Participants take both…
Phase 2 • Sponsor: Aadi Bioscience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC